The global market for cancer therapeutics and supportive care drugs was valued at around USD 117.8 billion in 2016 and is expected to reach USD 222.9 billion by 2023, growing at a CAGR of around 9.7% during the forecast period of 2017 to 2023. Cancer, also called malignancy, is an abnormal growth of cells. There are more than 100 types of cancer, including breast cancer, skin cancer, lung cancer, colon cancer, prostate cancer, and lymphoma. Symptoms vary depending on the type. Cancer treatment may include chemotherapy, radiation, and/or surgery. 2015 year saw a new high in the number of US food and drug administration approvals of new pharmaceuticals, including new molecular entities (NMEs) and new Biologic License Applications (BLAs), amounting to a total of 45 NMEs and BLAs in all disease states compared with 41 approved in 2014 and much fewer (27) in 2013. Of these 45 NMEs and BLAs entering the market last year, 16 were novel therapies for cancer, providing patients new hope through novel treatment options and new mechanisms of action. New trends in oncology drug development are reflected in the increasing use of biotechnology in the development of anticancer drugs, including immunotherapies or monoclonal antibodies, adoptive-cell therapies, and new vaccines.